1. Introduction {#sec1}
===============

The overuse and inappropriate application of antibiotics is well known to lead to the emergence of antibiotic resistance---and even more challenging---to an increase of multidrug resistances (MDR) among several bacterial species.^[@ref1]^ MDR *Mycobacterium tuberculosis*, or Gram-negative bacteria with extended-spectrum β-lactamase production (e.g., *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Enterobacter* species) and among Gram-positive bacteria, especially *Staphylococcus aureus* (*S. aureus*), have become a major problem for the global healthcare system by increasing healthcare costs due to high morbidity and mortality rates and prolonged hospitalization.^[@ref2],[@ref3]^

A central issue in the development of MDR bacteria is related to the fact that classical treatment strategies often lead to insufficient levels of anti-infectives in various niches of the host such as the intracellular milieu, rendering the treatment less efficient and increasing the threat that pathogens become resistant.^[@ref2]−[@ref6]^*S. aureus*, for example, is known to establish intracellular infection reservoirs because of internalization and persistence in several host cells (e.g., mast cells, dendritic cells, macrophages, epithelial cells, and osteoblasts).^[@ref3],[@ref7]−[@ref11]^ Certain *S. aureus* subpopulations (small colony variants) are even well adapted to persist for long periods in the intracellular milieu,^[@ref12]−[@ref15]^ and they are associated with chronic, relapsing, and therapy-refractory infections such as osteomyelitis or cystic fibrosis.^[@ref16]−[@ref19]^

Promising concepts to conquer these problems and to restrict antimicrobial resistance relate to the development of new antimicrobial agents or---equally important---the evolution of more efficient dosage forms of conventional antibiotics for obtaining sufficient concentration levels in the intracellular milieu to guarantee bacterial eradication.^[@ref2]−[@ref6]^ Typically, the maximum concentration of antibiotics, however, is limited by solubility/availability (in blood, cells, tissue), penetration (through membranes), retention time (due to biodegradation or excretion), as well as by induced side effects. Higher concentrations within the intracellular milieu could be achieved via more efficient uptake into infected cells and tissue. In this regard, several nanoparticle-based concepts were suggested (e.g., tuberculosis treatment)^[@ref20],[@ref21]^ that use the different uptake of nanoparticles (i.e., phagocytosis and pinocytosis) in comparison to molecular antibiotics in solution (i.e., via ion channels or passive diffusion through lipid double layers).^[@ref22],[@ref23]^

Nanoparticle-based concepts for antibiotic delivery predominately relate to organic polymers and micelles^[@ref24]−[@ref27]^ as well as inorganic compounds (e.g., SiO~2~, Fe~2~O~3~, Ag, and Au),^[@ref20],[@ref21],[@ref28]−[@ref34]^ in which the antibiotic is encapsulated. These concepts intrinsically have the disadvantage of comparably low drug contents (typically \<10 wt %) in mainly nonactive matrices as the majority material. In some cases, moreover, elaborate, multistep synthesis is needed and/or the particle size is too large (\>150 nm) for what is considered as optimal for biomedical nanoparticle applications (50--100 nm).^[@ref20],[@ref21],[@ref28]−[@ref34]^ All in all, nanoparticular antibacterial agents appear to have great potential to revolutionize the diagnosis and treatment of bacterial infections.^[@ref35]−[@ref40]^

To address the challenge of intracellular MDR bacteria, we here suggest saline \[ZrO\]^2+^\[CLP\]^2--^ inorganic--organic hybrid nanoparticles (IOH-NPs) as a novel nanocontainer concept to deliver antibiotics with extremely high concentration directly to *S. aureus* in intracellular niches. \[ZrO\]^2+^\[CLP\]^2--^ is an insoluble, saline compound, made in water, which contains an unprecedented high load of 82 wt % of antibiotic \[CLP\]^2--^ (CLP: clindamycinphosphate). CLP is a clinically approved pro-drug for the active last resort antibiotic clindamycin (CL).^[@ref41],[@ref42]^ Both---CLP and CL---are highly bacteriostatic, bactericidal (at higher concentration), and widely used to treat staphylococcal infections---but by now only in dissolved, free form.^[@ref41],[@ref42]^

2. Results and Discussion {#sec2}
=========================

2.1. Material Synthesis and Characterization {#sec2.1}
--------------------------------------------

\[ZrO\]^2+^\[CLP\]^2--^ was prepared by injecting an aqueous solution of ZrOCl~2~ × 8H~2~O to aqueous solutions of Na~2~(CLP) at 55 °C ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). The synthesis compares to our previously presented concept of phosphate-based IOH-NPs with a general composition \[ZrO\]^2+^\[R~Function~OPO~3~\]^2--^.^[@ref43],[@ref44]^ Herein, the inorganic cation \[ZrO\]^2+^ and a functional organic anion \[R~Function~OPO~3~\]^2--^ together form a saline hybrid material. \[ZrO\]^2+^ as the cation and a phosphate group as part of the organic anion guarantee for the insolubility of the IOH-NPs in water ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). On the basis of different functional organic anions, a wide range of IOH-NPs entailing various functionalities such as fluorescence, magnetism, or drug delivery can be realized so that the IOH-NPs become suitable for multimodal imaging and/or cancer treatment ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S1).^[@ref43],[@ref44]^ Here, we can expand the material concept to antibiotic nanocarriers for the first time. To obtain the saline \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs and colloidally stable suspensions, particle nucleation and particle growth have to be performed precisely ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf)).^[@ref45]^ \[ZrO\]^2+^\[CLP\]^2--^ is insoluble in water and can be easily suspended in polar solvents such as water, ethanol, diethylene glycol, or biological buffers (e.g., HEPES and aqueous dextran). Slow dissolution of the \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs in an active metabolism---similar to CLP as conventional pro-drug in solution---results in the release of CL as the active drug in the presence of phosphatases.^[@ref41],[@ref42]^

![Scheme illustrating the water-based synthesis of \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs: (a) structure of antibiotic \[CLP\]^2--^ anion; (b) photograph of aqueous \[ZrO\]^2+^\[CLP\]^2--^ suspension; (c + d) electron microscopy of nanoparticles; and (e) FT-IR spectra \[with Na~2~(CLP) as reference\].](ao-2018-006378_0001){#fig1}

On the basis of the good availability of CL as a standard anti-infective and the low-cost aqueous synthesis, \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs can be obtained in large quantities and concentrated suspensions (up to 20 mg/mL). Scanning electron microscopy (SEM) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}c,d) confirms the presence of spherical nanoparticles with a mean diameter of 44 ± 11 nm (calculated by statistical evaluation of 100 particles). The hydrodynamic diameter (73(14) nm) obtained via dynamic light scattering is as large as the value obtained by SEM ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S2), which can be ascribed to the high polarity of water and the resulting expanded rigid solvent shell. Moreover, the absence of any specific surface stabilizer on the as-prepared IOH-NPs needs to be taken into account, which facilitates the synthesis and which allows avoiding any eventual toxic effect of a stabilizer. Energy-dispersive X-ray analysis (EDX), Fourier-transform infrared spectroscopy (FT-IR), thermogravimetry (TG), and elemental analysis (EA) validate the chemical composition of \[ZrO\]^2+^\[CLP\]^2--^ as a new compound. EDX and FT-IR qualitatively prove the presence of \[ZrO\]^2+^ and \[CLP\]^2--^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}e). Quantification via total organics combustion (TG) shows a weight loss of 66% fitting well with the expectation (calcd. 68%) ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S3). EA data of 33.0 wt % C, 5.6 wt % H, 5.6 wt % N, 4.6 wt % S also agree with the expectation (calcd C: 35.0, H: 4.6, N: 5.3, S: 5.3 wt %).

2.2. Biocompatibility and Cell Uptake {#sec2.2}
-------------------------------------

Biocompatibility and cell uptake were verified by feeding \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs to murine bone marrow derived macrophages (BMDMs)---a cell type generally showing high uptake rates of nanoparticles.^[@ref45]^ BMDMs were grown in sterile 4-chamber slides to form confluent cell monolayers and incubated for 6 h in the presence of \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs. Within this time period, numerous \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs were phagocytosed and appear within primary lysosomes (pLs) either individually or as electron dense clusters ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a,b: red circles, red arrowheads). *S. aureus* cells are characteristically dispersed within the cytoplasm of infected BMDMs and actively grow within the state of binary fission ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}c). To study the impact of \[ZrO\]^2+^\[CLP\]^2--^ on the viability of intracellular *S. aureus*, infected BMDMs were incubated for 4 h ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}d), 6 h ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}e), and 12 h ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}f,g) with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs and examined by electron microscopy. Within BMDMs, individual bacterial cells (BCs) appear surrounded by clusters of \[ZrO\]^2+^\[CLP\]^2--^ within in close distances \<500 nm ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}d,g: red stars). After 12 h of incubation with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs, the BC shows electron transparencies produced by alterations within the cell wall/subcell wall regions and the plane of binary fission that is associated with an "en-gros" change in cell morphology ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}g). Such cellular defects (CD: black arrows) indicate antibiotic activity and death of the BC.

![Electron microscopy of murine macrophages, infected with *S. aureus* SH1000 and treated with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs: (a) survey of "en face"-sectioned, unstained macrophages, treated with \[ZrO\]^2+^\[CLP\]^2--^ for 6 h (red arrowheads indicate IOH-NP clusters). (b) Detailed view of IOH-NP clusters (red arrowheads) and individual IOH-NPs (red circles) within the pL. (c) Macrophage infected for 12 h with *S. aureus* without IOH-NPs (infection control). (d--g) Macrophages treated with \[ZrO\]^2+^\[CLP\]^2--^ 12 h before infection with *S. aureus* and after 4, 6, and 12 h of incubation (IOH-NP clusters indicated by red stars). Indicators: pL: primary lysosome, N: nucleus, BC: bacterial cell, CD: cellular defects, bR: bacterial remnant.](ao-2018-006378_0002){#fig2}

To validate the presence of \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs within lysosomes, parallel electron energy-loss spectroscopy and electron spectroscopic imaging (ESI) were performed on unstained 40 nm ultrathin sections of uninfected and *S. aureus*-infected BMDMs incubated with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a,b; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S4). This allows discriminating \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs from other electron dense nanostructures such as ferritins or Fe~2~O~3~ particles that can be present in BMDMs. Accordingly, Zr-*M45* elemental maps show distinct Zr-*M45* intensities, congruent with \[ZrO\]^2+^\[CLP\]^2--^ clusters of pLs for uninfected ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a) and *S. aureus*-infected macrophages ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b), indicating the presence and high load of internalized \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs. To validate efficient uptake and to ensure the intracellular localization of the IOH-NPs, immunofluorescence microscopy was performed using fluorescence-marked \[ZrO\]^2+^\[(CLP)~0.995~(DUT)~0.005~\]^2--^ (DUT: dyomics-647 uridine triphosphate; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S1) and gfp-expressing *S. aureus* bacteria (gfp: green fluorescence protein). Similar to the results of EELS and ESI, the macrophages are highly loaded with fluorescent IOH-NPs, which are found in close proximity to the intracellular bacteria ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c,d). The data indicate a potential localization of IOH-NPs within primary lysosomal compartments. However, further co-localization studies (e.g., using lysotracker) are needed to gain deeper insights in the molecular and cellular uptake mechanisms of IOH-NPs into the host cells.

![Localization of \[ZrO\]^2+^\[CLP\]^2--^ in BMDM cells: (a) Zr elemental map (Zr-*M45* in red) of macrophage treated for 3 h with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs and (b) after infection for 12 h with *S. aureus* and treated for 3 h with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs (indicators: BC: bacterial cell, N: nucleus). (c,d) Fluorescence microscopy with \[ZrO\]^2+^\[(CLP)~0.995~(DUT)~0.005~\]^2--^ IOH-NPs (purple), *S. aureus* (turquoise), and cellular nuclei (blue, stained with DAPI). Macrophages infected with gfp-expressing *S. aureus* strain SH1000 at an MOI of 10:1 for 1 h followed by co-cultivation with \[ZrO\]^2+^\[(CLP)~0.995~(DUT)~0.005~\]^2--^ for 6 h. Enlargement (d) shows co-localization of gfp-expressing *S. aureus* (turquoise) and \[ZrO\]^2+^\[(CLP)~0.995~(DUT)~0.005~\]^2--^ IOH-NPs (purple).](ao-2018-006378_0003){#fig3}

2.3. Antibiotic Effect {#sec2.3}
----------------------

Having demonstrated that the \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs were efficiently internalized by BMDMs, their potential toxic effect on cell viability was assessed by measuring the lactate dehydrogenase (LDH) released into the supernatant by \[ZrO\]^2+^\[CLP\]^2--^-treated BMDMs. Generally, the release of the cytoplasmic enzyme LDH into the culture medium is an indication of plasma membrane disruption and cell damage. However, no significant levels of LDH were observed in the supernatant of \[ZrO\]^2+^\[CLP\]^2--^-treated and untreated BMDMs ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S5). These results clearly indicate a lack of toxicity of \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs for BMDMs after 24 h of incubation.

To verify if \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs (in suspension) have an advantage over free CLP (in solution) to kill intracellular *S. aureus*, professional phagocyte BMDMs and nonprofessional phagocytic human epithelial Hep2 cells were infected with the *S. aureus* strain SH1000 at a multiplicity of infection of 10 bacteria per 1 eukaryotic cell for 1 h. The infection was followed by treatment for 2 h with either \[ZrO\]^2+^\[CLP\]^2--^ (suspension) or dissolved CLP \[i.e., solution of Na~2~(CLP)\]. Untreated infected cells were used for comparison. Cells were harvested 4 h (nonhatched bars) and 24 h (hatched bars) after infection, washed twice with sterile phosphate-buffered saline, and lysed with ddH~2~O for 5 min to release intracellular bacteria. Thereafter, the number of viable intracellular bacteria was counted after platting serial dilutions on blood agar plates. As a result, the number of viable intracellular bacteria is significantly lower in macrophages ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a) as well as in Hep2 cells ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b) after treatment with \[ZrO\]^2+^\[CLP\]^2--^ (suspension) compared to untreated cells and cells treated with dissolved CLP (solution). Most remarkably, solutions of free CLP do not show any effect on BMDMs 4 h after infection ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a), whereas the IOH-NPs significantly reduce the survival rate of intracellular *S. aureus*. In non-phagocytic Hep2 cells, a significant difference between \[ZrO\]^2+^\[CLP\]^2--^ (suspension) and dissolved CLP was also obtained 24 h after infection ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b), clearly indicating the advantage of the IOH-NP drug delivery concept for cells with low bacterial killing ability. All in all, this clearly demonstrates that CL is significantly more efficient at targeting intracellular *S. aureus* when delivered as \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs than in the dissolved free form.

![Intracellular survival of *S. aureus* within macrophages (BMDMs) (a) and epithelial Hep2 cells (b) 4 h (nonhatched bars) and 24 h (hatched bars) after infection (cells infected for 1 h with an MOI of 10:1; level of intracellular bacteria 1 h after infection referred to as 100%). Data with mean ± SD of three experiments (\*\*\**p* \< 0.0005, \*\**p* \< 0.005, \**p* \< 0.05).](ao-2018-006378_0004){#fig4}

To determine if the superior bactericidal efficiency of CL-loaded \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs over dissolved, free CL is provoked by a more efficient antibiotic penetration and retention in the intracellular milieu, the loading kinetics of either \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs (suspension) or free CL (solution) into eukaryotic cells was analyzed in BMDMs. Hence, BMDMs were incubated with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs, dissolved CLP ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}) and dissolved CL hydrochloride (CL, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S6) for 1, 2, and 4 h. The amount of intracellular CL was determined in BMDM lysates by high-performance liquid chromatography (HPLC)--mass spectrometry (MS)/MS ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf)) to determine the intracellular CL levels ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S6).

![Intracellular CL levels within macrophages 1, 2, and 4 h after co-cultivation with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs and dissolved CLP at identical concentrations (50 μg CLP/mL): (a) illustration of uptake and cell treatment; (b) internalized CL after treatment with dissolved CLP (white bars), \[ZrO\]^2+^\[CLP\]^2--^ (red bars), lysates of untreated cells (negative control, gray bars). Data measured by HPLC--MS/MS; mean ± SD of triplicate samples (\*\*\**p* \< 0.001).](ao-2018-006378_0005){#fig5}

As a result, the internalized CL concentration in macrophages turned out to be 70-times higher after 1 h of incubation when treated with \[ZrO\]^2+^\[CLP\]^2--^ suspensions in comparison to CLP and CL in solution ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S6, Tables S1, and S2). After 4 h, the internalized CL concentration increases even further and is about 150-times higher after treatment with \[ZrO\]^2+^\[CLP\]^2--^ suspensions ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S6, Tables S1, and S2). The intracellular levels of CLP reached 1.027 μg per mL in macrophages incubated up to 4 h with the IOH-NPs (suspension). This concentration exceeds the minimal inhibitory concentration of CLP, which was determined as \<0.625 μg per mL ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figure S7). In contrast to the IOH-NP suspensions, the concentration of intracellular CLP after co-cultivation of cells with dissolved CLP remained in the subinhibitory range \<0.02 μg per mL. The significantly higher CLP levels reached via the IOH-NP treatment, therefore, is highly promising to address and eventually to solve the challenges related to MDR formation.

The remarkable increase of CLP uptake using IOH-NPs can be attributed to a more efficient uptake of the IOH-NPs by cellular processes such as phago-/pinocytosis and the active acquisition of the IOH-NPs as a phosphate source.^[@ref43],[@ref44],[@ref46],[@ref47]^ These findings coincide with the efficient uptake and the intracellular localization of the \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs as shown by EELS, ESI ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a,b), and immunofluorescence microscopy ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c,d). The uptake of \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs in BMDMs, finally, shows clear time and concentration dependency ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf): Figures S8 and S9). The extremely high uptake of \[ZrO\]^2+^\[CLP\]^2--^ by BMDMs can become even more interesting because macrophages can abandon the blood system to attack *S. aureus* at difficult-to-reach niches of the host.^[@ref48]^

3. Conclusions {#sec3}
==============

In sum, \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs represent a novel nanoparticle-based strategy to treat persisting and recurrent *S. aureus*-caused infections. \[ZrO\]^2+^\[CLP\]^2--^ contains an unprecedented high amount (82 wt %) of clinically approved CLP and shows high uptake at low toxicity. Most interestingly, the IOH-NP suspensions allow 70--150-times higher drug concentration (after 1--4 h of incubation) than the free drug in solution at difficult-to-reach intracellular infection sites. This offers unique options for improved drug delivery to eradicate intracellular bacterial reservoirs during chronic and difficult-to-treat infections. Because macrophages are not limited to the blood system, they can---after loading with \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs---also attack multiresistant bacteria in various difficult-to-reach niches of the host with the anti-infective in very high concentrations. In principle, the material concept and delivery strategy can be also transferred to other antibiotics as well as to treat other multiresistant bacteria including the relevant species of *Klebsiella*, *Pseudomonas*, or *Enterobacter*.

4. Experimental Section {#sec4}
=======================

4.1. Synthesis of \[ZrO\]^2+^\[CLP\]^2--^ IOH-NPs {#sec4.1}
-------------------------------------------------

Na~2~(CLP) (25 mg, Aldrich, 95.7%) was dissolved in water (50 mL). The pH of this solution was adjusted to 7.0 upon the addition of diluted NaOH (140 μL, 0.5 M). Thereafter, an aqueous solution (5 mL) of ZrOCl~2~ × 8H~2~O (4.25 mg, Aldrich, 99%) was injected. After 2 min of intense stirring, the nanoparticles were separated via centrifugation (25 000 rpm, 15 min). To remove all remaining salts, the colorless \[ZrO\]^2+^\[CLP\]^2--^ was resuspended in and centrifuged from H~2~O three times. Subsequent to redispersion, highly stable colloidal suspension in water can be obtained ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b00637](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b00637).Details regarding analytical techniques for material characterization, synthesis of \[ZrO\]^2+^\[CLP\]^2--^ and fluorescence-marked \[ZrO\]^2+^\[(CLP)~0.95~(DUT)~0.05~\]^2--^ IOH-NPs, material characterization, and biological studies ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00637/suppl_file/ao8b00637_si_001.pdf))
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